Opthea Limited ( ($AU:OPT) ) has shared an update. Opthea Limited has requested a voluntary suspension of its securities from trading on the ASX ...

Trading in shares of Opthea is halted in the U.S. and Australia ahead of planned update by the clinical-stage biopharmaceutical company on a late-stage study of its lead product candidate ...

The high-profile stockpicker is the eye disorder treatment hopeful’s biggest shareholder. Ahead of the results of a crucial ...

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

Opthea Limited ( ($AU:OPT) ) has provided an update. Opthea Limited has requested a trading halt on its securities pending the announcement of the ...

We recently published a list of 10 Best Australian Stocks to Buy According to Billionaires. In this article, we are going to ...

Opthea Limited’s OPT share price has dipped by 11.56%, which has investors questioning if this is right time to buy.

On St Patrick's Day, investors hope for the luck of the Irish ahead of Opthea's key trial update and Imricor's ambitious fund ...

Baseline angiographic lesion characteristics predictive of clinical responsePublished in peer-reviewed journal Ophthalmic Surgery, Lasers and ...

MELBOURNE, Australia and PRINCETON, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage ...

Opthea Limited has announced the publication of Phase 2b data on sozinibercept, a novel combination therapy for treating wet age-related macular degeneration (wet AMD), in the journal Ophthalmic ...

MELBOURNE, Australia and PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage ...